Gerstein, MD, MSc, FRCPC , a professor and population health institute chair in diabetes research at McMaster University and Hamilton Health Sciences in Canada, said that evidence from the REWIND trial and other findings are certainly supportive of the hypothesis, but more research is needed
Whether you are considering this product or simply trying to understand the GLP-1 fat loss landscape , you will leave with a clear picture of what works, what does not, and where to focus your attention instead
The diabetes medication turned weight-loss miracle drug, Ozempic, and others like it, may be adding yet another use-case to their name: addiction cravings reducer
So, to mitigate these issues, it is essential to stay hydrated , monitor urine output , and report any significant changes to healthcare providers
The cumulative five-year risks of NAION and ION in diabetes patients on semaglutide were 0.065% and 0.08%, respectively
Speakers: Bill Giebler Content & insights director, New Hope Network Melissa Dunn Executive vice president of marketing & communications, Suzy Read more about: Sponsored Content